Filing Flows › BioScience Health Innovations (BHIC) › Q2 2026
BioScience Health Innovations (BHIC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
BioScience Health Innovations (BHIC) reported revenue of $1.0M for the second quarter 2026 (Q2 2026), -41% from a year earlier and +38% from the quarter before. Operating margin was -21.0%, net loss $186K (17.9% of revenue).
BioScience Health Innovations, Q2 2026: revenue $1.0M (-41% year over year), operating margin -21.0%, net loss $186K, operating cash flow −$542K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | +38% | -41% |
| Operating profit | −$218K | — | -148% |
| Net earnings | −$186K | — | -141% |
| Operating cash flow | −$542K | — | -290% |
What changed
Revenue was $1.0M in Q2 2026, down 41% year over year and up 38% from the previous quarter.
Gross margin was 63.6%, up 2.5 points from Q2 2025. Operating costs exceeded revenue by $218K, an operating margin of -21.0%. Operating expenses grew 42% against a revenue fall of 41%. The fastest-growing cost line was Research & development (+664%). The quarter ended with a net loss of $186K, narrower than the previous quarter's $230K loss.
Operating cash flow was −$542K. Working capital and other items used $356K.
Questions
What was BioScience Health Innovations' revenue in the second quarter 2026?
BioScience Health Innovations (BHIC) reported revenue of $1.0M for the second quarter 2026 (Q2 2026), -41% from a year earlier and +38% from the quarter before.
Was BioScience Health Innovations profitable in the second quarter 2026?
Operating loss was $218K (-21.0% of revenue) and net loss $186K.